MK-677: ibutamoren, explained

What it is — and what it isn't

MK-677, also called ibutamoren (development code MK-0677), is an orally active, non-peptide small molecule that acts as a selective agonist at the ghrelin receptor (GHS-R) — a growth-hormone secretagogue. It mimics the hormone ghrelin to stimulate the pituitary to release GH, which in turn raises IGF-1.

Two corrections, because the market gets this wrong constantly: MK-677 is not a SARM (SARMs bind the androgen receptor; MK-677 binds the ghrelin receptor — completely different) and it is not a peptide (it's a small molecule, taken as a pill or oral liquid, not an injectable peptide). It's listed here on the peptides hub because that's where people look for it and because it's run for similar GH-axis goals — but mechanistically it stands apart.

What the trials showed

Unlike most research compounds, MK-677 has real human clinical-trial data. Merck investigated it for age-related muscle loss, hip-fracture recovery, GH deficiency and Alzheimer's. The key trial — Nass et al., 2008, Annals of Internal Medicine (2-year, randomized, placebo-controlled; 65 healthy adults aged 60–81, 25 mg/day) — found 24-hour GH rose ~1.8-fold and IGF-1 ~1.5-fold (restored toward young-adult levels), with fat-free mass up ~1.1 kg over 12 months. Crucially, there was no improvement in strength or physical function, and insulin sensitivity declined (fasting glucose up, HbA1c up ~0.2%).

The honest, load-bearing part: the development program was discontinued. An Alzheimer's Phase 2 trial reported it was ineffective at slowing progression. A hip-fracture trial was stopped early on a safety signal — congestive heart failure in more MK-677 participants than placebo (a fluid-retention/CHF concern). It reached Phase 2, no New Drug Application was ever submitted, and it was never approved for any indication. The lean-mass biomarker story is real; the "it's a proven, safe anti-aging drug" story is not.

The numbers — half-life vs the 24-hour myth

This is the most-confused pharmacology point. MK-677 is taken orally, once daily. Its elimination half-life is short — about 4–6 hours (characterized in animals). But a single oral dose keeps IGF-1 elevated for roughly 24 hours, which is what makes once-daily dosing work.

Many vendor pages claim a "24-hour half-life" — that's incorrect. It conflates the duration of IGF-1 elevation (≈24 h, a downstream effect) with the plasma elimination half-life (≈4–6 h). The distinction matters because it changes how you think about timing and accumulation. Trials used 25 mg/day; the commonly reported range is 10–25 mg/day — presented as what's reported, not a recommendation. Because it's oral, there's no bacteriostatic-water reconstitution step the injectable peptides need; if it's sold as an oral liquid, it's dosed by milligrams of solution.

Side effects — worth taking seriously

MK-677 has a more concrete side-effect profile than most compounds in this space, which is worth stating plainly rather than glossing:

• Strong appetite increase — expected from a ghrelin-receptor agonist; the most consistently reported effect.
• Water retention / edema and swelling, sometimes lethargy or fatigue.
• Higher fasting blood glucose and reduced insulin sensitivity — clinically demonstrated (Nass 2008); relevant for anyone with prediabetes or diabetes, and a reason fasting glucose/HbA1c monitoring is sensible.
• Raised IGF-1, with a theoretical (not demonstrated) proliferative concern from chronic elevation.
• Congestive-heart-failure risk signal in older/vulnerable populations — the reason a trial was stopped early, and a concern the FDA has cited.

Tracking MK-677 in OptiPin

If you are tracking an oral GH-axis compound, OptiPin treats it like any other entry — without endorsing it:

• Daily oral dose log + reminders — record the once-daily dose and get reminded on the due day (no injection-site rotation needed — it's oral).
• IGF-1 & glucose tracking — log bloodwork (IGF-1, fasting glucose, HbA1c) over your dose timeline; given the demonstrated insulin-sensitivity effect, this is the monitoring that actually matters here.
• Weight & appetite notes — log weight and appetite over time, since increased appetite and water weight are the two most predictable effects.
• OptiInsight analysis — OptiPin's AI reads the full record (doses, labs, weight, symptoms) and surfaces what moved with what.
• Supply tracking — log the bottle/quantity; OptiPin estimates how long it lasts and warns before you run out.